Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Raises $10.5M In Venture Funding

Premium

PITTSBURGH--Cellomics, a company here whose drug discovery technology platform includes proprietary bioinformatics software, has raised $10.5 million in private venture funding. The venture syndicate was led by InterWest Partners and Axiom Venture Partners, along with Delphi Ventures and Oxford Bioscience Partners. Gerard Klauer Mattison served as investment consultants.

Previous investors in the company, which was formerly known as BioDx, include Carl Zeiss, Komasta Properties, Tycho Investors, and the founders. Cellomics focuses on cell-based screening technologies for target validation and lead optimization for new drug candidates. The company offers an integrated screening platform that includes fluorescence assays, a high-content screening system, and bioinformatics software, all designed to provide detailed biological information about a drug candidate's physiological effects on specific cellular targets.

In addition, Cellomics announced, it is developing a proprietary database product and what it called a "next-generation, cell-based screening platform," known as the CellChip System, plus the company will comarket an ultrahigh-throughput screening system, as well as its high-content screening system, through an exclusive, worldwide alliance with Carl Zeiss Jena. Cellomics was founded by Lansing Taylor, Alan Waggoner, Terry Dunlay, Michel Nederlof, John Boles, and LeRoy Metz.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.